XML 73 R61.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information - Schedule of Financial Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Jan. 31, 2025
Mar. 31, 2025
Mar. 31, 2024
Operating Expenses:      
Research and development   $ 2,602 $ 3,241
Operating loss   (5,847) (6,601)
Other income, net   (105) (187)
Benefit from income taxes $ 962 (962) (798)
Net loss   (4,724) (5,401)
Reportable Segment      
Operating Expenses:      
Research and development   2,602 3,241
General and administrative   3,245 3,360
Investor relations/public relations/communications   331 285
Finance   629 580
Legal   224 671
Business development   127 172
Share based compensation expense   404 368
Other   386 152
Operating loss   (5,847) (6,601)
Other income, net   161 402
Benefit from income taxes   (962) (798)
Net loss   (4,724) (5,401)
Cash and marketable securities   25,833 43,349
Reportable Segment | Segment Reporting, Reconciling Item, Corporate Nonsegment      
Operating Expenses:      
General and administrative   1,144 1,132
Reportable Segment | BOLSTER trial      
Operating Expenses:      
Research and development   788 1,270
Reportable Segment | ASCEND trial      
Operating Expenses:      
Research and development   21 44
Reportable Segment | Chemistry, manufacturing and controls      
Operating Expenses:      
Research and development   220 655
Reportable Segment | Clinical department      
Operating Expenses:      
Research and development   1,156 1,133
Reportable Segment | Other      
Operating Expenses:      
Research and development   $ 417 $ 139